Free Trial
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$6.07
-7.5%		$14.52
$4.37
▼
$31.35
$784.99M-0.382.26 million shs1.45 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$43.23
+0.3%		$43.61
$29.45
▼
$60.91
$3.47B1.951.14 million shs450,111 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$25.42
-4.6%		$32.64
$25.28
▼
$43.15
$3.20B0.663.20 million shs4.94 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$33.88
-1.6%		$52.45
$33.52
▼
$72.66
$3.27B0.61.39 million shs974,440 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-7.08%-5.34%-28.54%-77.23%+42.30%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.07%-3.45%+5.48%-27.56%+26.46%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-5.96%-6.10%-16.67%-29.52%-21.41%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-3.88%-5.88%-41.31%-49.17%-13.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$6.07
-7.5%		$14.52
$4.37
▼
$31.35
$784.99M-0.382.26 million shs1.45 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$43.23
+0.3%		$43.61
$29.45
▼
$60.91
$3.47B1.951.14 million shs450,111 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$25.42
-4.6%		$32.64
$25.28
▼
$43.15
$3.20B0.663.20 million shs4.94 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$33.88
-1.6%		$52.45
$33.52
▼
$72.66
$3.27B0.61.39 million shs974,440 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-7.08%-5.34%-28.54%-77.23%+42.30%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.07%-3.45%+5.48%-27.56%+26.46%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-5.96%-6.10%-16.67%-29.52%-21.41%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-3.88%-5.88%-41.31%-49.17%-13.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
2.86
Moderate Buy$33.27448.60% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.64
Moderate Buy$55.7829.04% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.75
Moderate Buy$99.44291.27% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.87
Moderate Buy$70.14107.01% Upside

Current Analyst Ratings Breakdown

Latest ALMS, VCYT, XENE, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$87.00 ➝ $85.00
10/6/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$73.00
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/2/2026
Alumis Inc. stock logo
ALMS
Alumis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/2/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/2/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
9/28/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$90.00
9/24/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C+) ➝ Hold (C)
9/23/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$83.00 ➝ $87.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$120.00
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$24.05M32.64N/AN/A$2.88 per share2.11
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M6.72$1.46 per share29.55$16.57 per share2.61
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M436.73N/AN/A$7.53 per share4.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$243.32M-$3.86N/AN/AN/A-5,933.46%-93.15%-74.50%11/12/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.4130.6328.07N/A20.37%9.26%8.61%11/3/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)

Latest ALMS, VCYT, XENE, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4111N/AN/AN/A$147.16 millionN/A
11/2/2026Q3 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.13N/AN/AN/A$1.33 millionN/A
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Alumis Inc. stock logo
ALMS
Alumis
-$0.7670-$1.11-$0.3430-$1.11$3.65 million$1.66 million
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
7/30/2026Q2 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4103$0.54+$0.1297$0.31$144.59 million$150.32 million
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.74
6.74
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.16
8.80
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
33.70%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.60%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
239129.43 million85.82 millionN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
75580.39 million79.11 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65125.99 million119.31 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
36496.67 million93.85 millionOptionable

Recent News About These Companies

Bank of America Securities Sticks to Their Buy Rating for Xenon (XENE)
October 13 at 9:03 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XENE-Q/pressreleases/6740944/bank-of-america-securities-sticks-to-their-buy-rating-for-xenon-xene/
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why
October 13 at 1:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-hits-new-12-month-low-heres-why-2026-10-13/
Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded by Wall Street Zen to "Strong Sell"
October 11 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106676
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen
October 11 at 1:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-cut-to-strong-sell-at-wall-street-zen-2026-10-11/
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-xenon-pharmaceuticals-xene-getting-231010016.html
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
October 9, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/xenon-pharmaceuticals-xene-stock-may-141401053.html
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376617/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-sets-new-1-year-low-heres-why-2026-10-06/
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Guggenheim
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091629
Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-guggenheim-reaffirms-buy-rating-for-xenon-pharmaceuticals-nasdaq-xene-2026-10-06/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 5, 2026  |  biospace.comB
Xenon CFO buys 15,000 shares
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084186
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082446
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082444
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from Brokerages
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081952
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-xenon-pharmaceuticals-inc-nasdaq-xene-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-10-03/
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying Activity
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081757
Wall Street Zen Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Sell"
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081512
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Lifted to "Sell" by Wall Street Zen
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-stock-lifted-to-sell-by-wall-street-zen-2026-10-03/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  financialpost.comF
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
An oil tanker anchored near a port terminal with storage tanks and hills visible in the background.
The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
By Thomas Hughes | September 17, 2026
Viking Therapeutics logo displayed among laboratory glassware, a vial, and a syringe in a lab setting.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
By Chris Markoch | September 23, 2026
Alumis stock logo

Alumis NASDAQ:ALMS

$6.06 -0.50 (-7.55%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$43.22 +0.12 (+0.27%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$25.42 -1.23 (-4.63%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$33.88 -0.54 (-1.56%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas